Heart failure (HF) imposes a large and growing burden on the population, with a prevalence that is projected to increase to more than 8 million adults by 2030. The high risk of morbidity and mortality ...
The sNDA for empagliflozin (Jardiance) to reduce the risk of cardiovascular death and hospitalization for heart failure and slow kidney function decline in adults with chronic heart failure with ...
Results for EMPEROR-Reduced have been highly anticipated, as they are expected to set off a new round of competition in the drug class, which was first developed to treat type 2 diabetes.
Please provide your email address to receive an email when new articles are posted on . “The EMPEROR-Reduced trial required patients to be treated for heart failure, but did not mandate specific doses ...
Please provide your email address to receive an email when new articles are posted on . Finerenone reduced risk for CV death and worsening heart failure vs. placebo in this patient population. Pooled ...
An analysis of more than 12,000 patients has found that the SGLT2 inhibitors dapagliflozin and empagliflozin reduce cardiovascular death or hospitalization for heart failure by 20% in heart failure ...
"These findings suggest that small variations in the amount of fluid given to a patient with sepsis, or the decision to give less fluid to a patient because they have heart failure, may not have a ...
In a trial, empagliflozin reduced the risks for heart failure hospitalization and renal outcomes in patients with heart failure with reduced ejection fraction. Empagliflozin reduces the risk for heart ...
The appraisal committee considered evidence submitted by Boehringer Ingelheim, a review of this submission by the evidence review group (ERG) and responses from stakeholders. See the committee papers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results